Whether the degree of glucose control independently predicts vein graft patency remains unclear.283 This uncertainty likely relates to the difficulty in separating the effects of glucose control from the progression of cardio- vascular disease in general but may also be complicated by the challenges and inaccuracy of graft patency assessment, small study sample sizes, and separation of the effects of associated conditions such as hyperlipidemia and hypertension. Patients having undergone surgical revascularization are at increased risk for further progression of CAD. Because there is no reason to surmise that CABG patients have any inher- ent protection from the effects of poorly controlled diabetes mellitus and because well-controlled blood sugar markedly improves survival in patients with cardiovascular disease,269 long-term glucose control should ideally be optimized for all CABG patients. Tight control of blood glucose is in a patient s best interest because cardiovascular disease is the most prevalent cause of morbidity and mortality in the dia- betic population. In terms of glucose management, CABG patients with dia- betes mellitus should receive coordinated medical care from a diabetes mellitus monitoring team. Such teams may include internists and endocrinologists, dieticians, pharmacists, and in certain cases, mental health professionals. Plasma glucose and levels should be followed up regularly, with appropri- ate adjustments made in insulin and oral hypoglycemic thera- pies. 